Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | Management of Irish ALK+ NSCLC patients with brigatinib

Jarushka Naidoo, MBBCh, Beaumont Hospital, Dublin, Ireland, discusses the impact of the changes of brigatinib reimbursement in Irish patients with ALK+ non-small cell cancer (NSCLC), based on the results of the Phase III ALTA-1L study (NCT02737501). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology)